Patents by Inventor Francesco Lozupone

Francesco Lozupone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of TM9SF4 as a biomarker for tumor associated exosomes
    Publication number: 20220349892
    Abstract: The present invention relates to extracellular microvesicles biomarkers for determining the tumour transformation status or presence of a tumour in a subject, and to the uses of such biomarkers and to diagnostics methods using such biomarkers. In particular, the methods and uses of the invention involve isolation of TM9SF4-positive extracellular vesicles and detection of the expression of a second biomarker, preferably selected from the group consisting of CD9 protein, miR-21 and RNU6.
    Type: Application
    Filed: May 5, 2022
    Publication date: November 3, 2022
    Inventors: Francesco LOZUPONE, Antonio Chiesi, Paolo Guazzi, Natasa Zarovni, Pietro Ferruzzi, Davide Zocco
  • Use of TM9SF4 as a biomarker for tumor associated exosomes
    Publication number: 20170146543
    Abstract: The present invention relates to extracellular microvesicles biomarkers for determining the tumour transformation status or presence of a tumour in a subject, and to the uses of such biomarkers and to diagnostics methods using such biomarkers. In particular, the methods and uses of the invention involve isolation of TM9SF4-positive extracellular vesicles and detection of the expression of a second biomarker, preferably selected from the group consisting of CD9 protein, miR-21 and RNU6.
    Type: Application
    Filed: June 5, 2015
    Publication date: May 25, 2017
    Applicant: Exosomics Siena S.p.A.
    Inventors: Francesco LOZUPONE, Antonio Chiesi, Paolo Guazzi, Natasa Zarovni, Pietro Ferruzzi, Davide Zocco
  • Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
    Publication number: 20150044695
    Abstract: A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.
    Type: Application
    Filed: September 5, 2014
    Publication date: February 12, 2015
    Applicant: HANSABIOMED OU
    Inventors: Francesco Lozupone, Mariantonia Logozzi, Stefano Fais, Antonio Chiesi, Natasa Zarovni
  • Monclonal antibodies, hybridomas and methods for use
    Publication number: 20120122118
    Abstract: The present invention provides monoclonal antibodies to TM9SF-proteins and hybridoma cell lines that produce the monoclonal antibodies to TM9SF4. This invention also provides a method for determining the level of TM9SF4-protein in biological fluid samples, tissue samples and in microvesicles such as exosomes, comprising kit for determining the level of TM9SF4 protein in human exosomes and other microvesicles, in tissue samples, and in biological fluids.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 17, 2012
    Applicants: PRIMM SRL, HANSABIOMED OU
    Inventors: Francesco Lozupone, Stefano Fais, Antonio Chiesi, Natasa Zarovni, Angela Simona Pontillo, Paolo Sarmientos
  • Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
    Publication number: 20120058492
    Abstract: A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.
    Type: Application
    Filed: November 7, 2011
    Publication date: March 8, 2012
    Applicant: HANSABIOMED OU
    Inventors: Francesco Lozupone, Stefano Fais, Mariantonia Logozzi, Antonio Chiesi, Natasa Zarovni
  • Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression
    Patent number: 8097407
    Abstract: This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: January 17, 2012
    Assignee: Hansabiomed OU
    Inventors: Francesco Lozupone, Stefano Fais
  • Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression
    Publication number: 20090191222
    Abstract: This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.
    Type: Application
    Filed: January 26, 2009
    Publication date: July 30, 2009
    Applicant: Hansabiomed OU
    Inventors: Francesco Lozupone, Stefano Fais